Mixed amphetamine salts: Difference between revisions
From Pharmacopedia
More actions
| [pending revision] | [pending revision] |
Terminology: medicine → med (shorter form per user preference) |
MDElliottMD (talk | contribs) Migrate <indication> tags to <problem> (Phase 2 of indications-to-problems rebuild) |
||
| Line 18: | Line 18: | ||
| intro = '''Mixed amphetamine salts (MAS)''' — marketed primarily as '''Adderall''' — is a 3:1 mixture of dextroamphetamine and levoamphetamine salts (dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate). | | intro = '''Mixed amphetamine salts (MAS)''' — marketed primarily as '''Adderall''' — is a 3:1 mixture of dextroamphetamine and levoamphetamine salts (dextroamphetamine sulfate, amphetamine sulfate, dextroamphetamine saccharate, and amphetamine aspartate). | ||
Amphetamine was first synthesized in 1887 by Lazăr Edeleanu, then developed as a med in the late 1920s. "Adderall" was approved by the FDA in 1996, and has since become one of the most popular meds in the United States. Adderall/MAS is FDA-approved for attention-deficit hyperactivity disorder and narcolepsy. It is listed in Schedule II of the Controlled Substances Act, and so is tightly regulated in the United States as well as many other countries around the world. | Amphetamine was first synthesized in 1887 by Lazăr Edeleanu, then developed as a med in the late 1920s. "Adderall" was approved by the FDA in 1996, and has since become one of the most popular meds in the United States. Adderall/MAS is FDA-approved for attention-deficit hyperactivity disorder and narcolepsy. It is listed in Schedule II of the Controlled Substances Act, and so is tightly regulated in the United States as well as many other countries around the world. | ||
| indications = < | | indications = <problem ref="adhd" author="MDElliottMD"/> | ||
< | <problem ref="narcolepsy" author="MDElliottMD"/> | ||
< | <problem ref="trd-augment" author="MDElliottMD"> | ||
Off-label. | Off-label. | ||
</ | </problem> | ||
< | <problem ref="shift-work" author="MDElliottMD"> | ||
Off-label. | Off-label. | ||
</ | </problem> | ||
< | <problem ref="chronic-illness-cog" author="MDElliottMD"> | ||
Off-label. | Off-label. | ||
</ | </problem> | ||
< | <problem ref="impulsivity" author="MDElliottMD"/> | ||
< | <problem ref="distractibility" author="MDElliottMD"> | ||
Impoved sustained attention by decreasing distractibility | Impoved sustained attention by decreasing distractibility | ||
</ | </problem> | ||
| dosing = <titration slug="typical-adult" title="Typical Adult" author="MDElliottMD"> | | dosing = <titration slug="typical-adult" title="Typical Adult" author="MDElliottMD"> | ||
Start at 5 mg XR; may increase by 5 mg each day until the desired effect is reached, up to 30 mg XR to start, and up to 60 mg XR eventually if necessary, in 10 mg increments. | Start at 5 mg XR; may increase by 5 mg each day until the desired effect is reached, up to 30 mg XR to start, and up to 60 mg XR eventually if necessary, in 10 mg increments. | ||